{"doi":"10.2217/fon-2020-1007","title":"MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma","abstract":null,"journal":"Future Oncology","year":2021,"id":623005,"datarank":0.6907755278982138,"base_score":4.605170185988092,"endowment":4.605170185988092,"self_citation_contribution":0.6907755278982138,"citation_network_contribution":0.0,"self_endowment_contribution":0.6907755278982138,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":99,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1609970,"name":"Minori Rosales","orcid":null,"position":1,"is_corresponding":false},{"id":316741,"name":"Hyun Cheol Chung","orcid":"0000-0002-0920-9471","position":2,"is_corresponding":false},{"id":1609971,"name":"Harry H Yoon","orcid":null,"position":3,"is_corresponding":false},{"id":260065,"name":"Lin Shen","orcid":"0000-0002-8798-4756","position":4,"is_corresponding":false},{"id":1176484,"name":"Markus Moehler","orcid":"0000-0003-4071-8562","position":5,"is_corresponding":false},{"id":1531943,"name":"Yoon-Koo Kang","orcid":null,"position":6,"is_corresponding":false},{"id":249518,"name":"Daniel V.T. Catenacci","orcid":"0000-0001-7517-8020","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma","abstract":"Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab, a humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2. Tebotelimab, an IgG4κ bispecific DART® molecule, binds PD-1 and lymphocyte activation gene 3 concomitantly, disrupting these nonredundant inhibitory pathways to further restore exhausted T-cell function. Here, we describe the design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and margetuximab plus tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma. Primary end points include objective response rate, overall survival and safety/tolerability. Clinical trial registration: NCT04082364 (ClinicalTrials.gov)","is_dataset_classified":null,"base_score":4.605170185988092,"endowment":4.605170185988092,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33263418","pmcid":null,"openalex_id":"https://openalex.org/W3109189796","authors":[],"funders":[{"funder_name":"MacroGenics, Inc.","grant_id":"","title":null},{"funder_name":"MacroGenics, Inc.","grant_id":"","title":null}],"total_grants":2,"fwci":7.3493,"citation_percentile":0.97970464,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":14},{"year":2022,"count":33},{"year":2023,"count":19},{"year":2024,"count":19},{"year":2025,"count":9},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.2217/fon-2020-1007","host_type":"journal"},{"url":"https://doi.org/10.2217/fon-2020-1007","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2020-1007","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33263418","host_type":"repository"},{"url":"https://ir.ymlib.yonsei.ac.kr/handle/22282913/184604","host_type":"repository"}],"fields_of_study":["Gastric Cancer Management and Outcomes","Gastrointestinal Tumor Research and Treatment","Cancer Immunotherapy and Biomarkers","Adenocarcinoma","Antibodies, Monoclonal","Antineoplastic Combined Chemotherapy Protocols","Biomarkers, Tumor","Esophageal Neoplasms","Esophagogastric Junction","Female","Humans","Male","Neoplasm Staging","Erb-b2 Receptor Tyrosine Kinases","Stomach Neoplasms","Treatment Outcome","Adenocarcinoma Of Esophagus"],"mesh_terms":["Adenocarcinoma","Antibodies, Monoclonal","Antineoplastic Combined Chemotherapy Protocols","Esophageal Neoplasms","Esophagogastric Junction","Female","Humans","Male","Neoplasm Staging","Stomach Neoplasms","Biomarkers, Tumor","Treatment Outcome","Receptor, ErbB-2","Erb-b2 Receptor Tyrosine Kinases"],"keywords":["Medicine","Trastuzumab","Monoclonal antibody","Chemotherapy","Tolerability","Oncology","Adenocarcinoma","Internal medicine","Cancer research","Antibody","Cancer","Immunology","Adverse effect","Breast cancer","Gastric cancer","PD-1","Her2","First-line Therapy","Lag-3","Immuno-oncology","Gastroesophageal Adenocarcinoma","Gastroesophageal Junction Cancer","Checkpoint Inhibitor","I-o Combination"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T21:55:30.436770Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}